11/5
11:19 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Royal Bank of Canada from $12.00 to $10.00. They now have a "sector perform" rating on the stock.
Low
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Royal Bank of Canada from $12.00 to $10.00. They now have a "sector perform" rating on the stock.
11/4
07:54 pm
advm
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/4
05:20 pm
advm
Adverum Biotechnologies: Q3 Earnings Snapshot [Yahoo! Finance]
Low
Report
Adverum Biotechnologies: Q3 Earnings Snapshot [Yahoo! Finance]
11/4
04:46 pm
advm
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones [Yahoo! Finance]
Low
Report
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones [Yahoo! Finance]
11/4
04:39 pm
advm
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones
Low
Report
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones
10/16
08:00 am
advm
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program
Medium
Report
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program
9/5
07:30 am
advm
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/4
04:05 pm
advm
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences
Low
Report
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences
8/15
02:08 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
8/14
10:03 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Truist Financial Co. from $60.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Truist Financial Co. from $60.00 to $40.00. They now have a "buy" rating on the stock.
8/13
02:22 pm
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Low
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
8/13
01:10 pm
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Royal Bank of Canada from $15.00 to $12.00. They now have a "sector perform" rating on the stock.
Low
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Royal Bank of Canada from $15.00 to $12.00. They now have a "sector perform" rating on the stock.
8/12
04:49 pm
advm
Adverum Biotechnologies: Q2 Earnings Snapshot [Yahoo! Finance]
Medium
Report
Adverum Biotechnologies: Q2 Earnings Snapshot [Yahoo! Finance]
8/12
04:05 pm
advm
Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights
Low
Report
Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights
8/7
01:35 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.